ISCT completes focus and program for 2022 Annual Meeting in San Francisco to cover cell and gene therapy ‘Bench to Bedside to Benefit’

By Audrey Le posted Mar 17, 2022 12:05

ISCT completes focus and program for 2022 Annual Meeting in San Francisco to cover cell and gene therapy ‘Bench to Bedside to Benefit’
Annual Meeting to provide venue for the entire cell and gene therapy sector to generate solutions to its major barriers of providing therapies to patients


Vancouver, Canada, March 17, 2022 - The International Society for Cell & Gene Therapy (ISCT), the global society of clinicians, researchers, regulators, technologists, and industry partners dedicated to the translation of cell and gene therapy (CGT) into safe and effective therapies to improve patients’ lives, today announces it has finalized the focus and program for the international ISCT 2022 Annual Meeting.

The Annual Meeting will be held at the Moscone West Convention Center in San Francisco, US, between May 4-7, 2022. ISCT 2022 will be an in-person event only, for the first time since the 2019 Annual Meeting in Melbourne, having held the 2020 and 2021 Annual Meetings virtually. The ISCT 2022 Annual Meeting will additionally celebrate the 30th milestone anniversary of the founding of ISCT.

The ISCT Annual Meeting is the largest global yearly summit event for all those involved in the cell and gene therapy sector. It gathers international experts from all stakeholders in the cell and gene therapy field across industry, academic and regulatory spheres. It will set the aims, policies, solutions, and consensus path forward for the sector in the next 12 months, addressing the biggest bottlenecks in cell and gene therapy development. The Annual Meeting is designed to connect cell and gene therapy translation professionals to educate, inspire, network and collaborate. 

The headline theme for the 2022 Annual Meeting is ‘Bench to Bedside to Benefit - Creating Value for Patients through CGT Translational Science’. The meeting will take an integrative approach across all stakeholders to address key topics spanning translational research and preclinical development through to clinical trials, regulatory approvals, commercialization and ultimately patient access. This includes over 30 highly interactive roundtables at the meeting, curated by ISCT’s 40+ standing committees and corporate partners. These roundtables will tackle the key issues, and provide solutions to the main barriers and challenges.

The 30+ roundtables will provide key stakeholders the platform to debate and provide consensus to guide ISCT and the wider sector on a full range of topics, barriers and milestones currently affecting cell and gene therapy today. This covers the full range of therapies, including innovation, clinical translation, product launch and patient access for CAR-Ts, MSCs, iPSCs, and a variety of gene therapies. The topics include the relationship between investors and the CGT sector, expanded access and hospital exemption, managing the CGT workforce and skills crisis, product development, managing risks, potency assays, toxicity, sterility, starting materials and donors, supply chains and Chain of Custody and Identity.

“At the thirtieth anniversary of ISCT, the cell and gene therapy sector is now delivering a range of therapies to patients and the market for a variety of conditions. This now means that ISCT needs to host its Annual Meeting that covers not just the sector’s ability to develop life changing therapies for patients, but how to get those therapies to treat patients - to move from bench to bedside to benefit,” said Bruce Levine, President, ISCT and Barbara and Edward Netter Professor in Cancer Gene Therapy, University of Pennsylvania Perelman School of Medicine. “This event will be vital for every single organization involved in every stage of bringing these therapies to patients, from generating return on investment to managing the supply chain. It will be vital for ISCT to provide the platform and venue for the sector to come together to discuss and provide solutions to the fresh challenges that are needed for patients to benefit from cell and gene therapies.”

The Presidential Plenary on May 4 is chaired by Bruce Levine, ISCT President and includes three speakers Fyodor Urnov, PhD, University of California Berkeley, Kristen Hege, MD, Bristol-Myers Squibb, and Carl June MD, University of Pennsylvania. It is entitled ‘Pioneering gene editing and gene modification for patient benefit - trailblazing new paths in design immunity’. There will also be a variety of plenary and concurrent session themes to the conference including science and innovation, translation to the clinic, first in human to clinical acceleration, launch and patient access.

About the International Society for Cell & Gene Therapy

Established in 1992, the International Society for Cell & Gene Therapy (ISCT) is a global society of clinicians, regulators, researchers, technologists, and industry partners with a shared vision to translate cell and gene therapy into safe and effective therapies to improve patients’ lives worldwide.

ISCT is the global leader focused on pre-clinical and translational aspects of developing cell and gene-based therapeutics, thereby advancing scientific research into innovative treatments for patients. ISCT offers a unique collaborative environment that addresses three key areas of translation: Academia, Regulatory, and Commercialization. Through strong relationships with global regulatory agencies, academic institutions, and industry partners, ISCT drives the advancement of research into a standard of care.

Comprised of over 2,400 cell and gene therapy experts across five geographic regions and representation from over 60 countries, ISCT members are part of a global community of peers, thought leaders, and organizations invested in cell and gene therapy translation. For more information about the society, key initiatives, and upcoming meetings, please visit:


Contact Information:

Image Box Communications
Neil Hunter / Michelle Boxall
Tel +44 (0)20 8943 4685 /